Phase II Study of Panitumumab Monotherapy in Chemotherapy-Naïve Frail or Elderly Patients with Unresectable <i>RAS</i> Wild-Type Colorectal Cancer: OGSG 1602
Tetsuji Terazawa(Osaka Medical and Pharmaceutical University), Taroh Satoh(Osaka University Hospital), Kazuhiro Yanagihara(Kansai Electric Power (Japan)), Yoshinori Kagawa(Osaka International Cancer Institute), Ken Konishi(Hyogo Prefectural Nishinomiya Hospital), Yukinori Kurokawa(The University of Osaka), Hironaga Satake(Kobe City Medical Center General Hospital), Masahito Kotaka(Shimizu (Japan)), Masayuki Hiraki(Osaka Health Science University), Toshio Shimokawa(Wakayama Medical University), Katsuya Ohta(Tokyo Medical and Dental University), Ken Nakata(Sakai Municipal Hospital), Takeshi Kato(Osaka National Hospital), Daisuke Sakai(Osaka International Cancer Institute), Masahiro Goto(Osaka Medical and Pharmaceutical University), Hiroko Hasegawa(Osaka National Hospital), Shiro Nakae(Sakai Municipal Hospital), Tatsushi Shingai(Kinki Central Hospital), Shingo Noura(Osaka Rosai Hospital), Hisato Kawakami(Tohoku University)
Cited by 19
Related Papers
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
|The Lancet Oncology|2021|411